BCL2 and neoplasm: Pharmacological inhibitors of anti-apoptotic proteins typically overexpressed in tumor cells, such as Bcl-2 and Bcl-xL, transcriptional inhibitors of the Bcl-2 gene, or small molecules that reactivates the wild-type function of mutant p53, have been developed [21].